Lemaitre Vascular (LMAT) 18.35 $LMAT LeMaitre V
Post# of 273258
Posted On: 09/03/2016 1:08:46 AM
Lemaitre Vascular (LMAT) 18.35 $LMAT
LeMaitre Vascular to Attend the 9th Annual Barrington Research Fall Investment Conference on September 8, 2016
GlobeNewswire - Thu Aug 25, 4:43PM CDT
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that JJ Pellegrino, Chief Financial Officer, will present at the 9 Annual Barrington Research Fall Investment Conference on Thursday, September 8, 2016 at the Four Seasons Hotel in Chicago, IL.
LMAT: 18.35 (+0.59)
LeMaitre Vascular to Participate in the Midwest IDEAS Investor Conference on August 30, 2016
GlobeNewswire - Tue Aug 16, 3:32PM CDT
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that George W. LeMaitre, Chairman & CEO, will present at the Midwest IDEAS Investor Conference on Tuesday, August 30, 2016 at the Hard Rock Hotel in Chicago, IL.
LMAT: 18.35 (+0.59)
Moving Average Crossover Alert: LeMaitre Vascular (LMAT)
Zacks Equity Research - Zacks Investment Research - Tue Aug 16, 10:31AM CDT
LeMaitre Vascular, Inc. (LMAT) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
LMAT: 18.35 (+0.59)
Will LeMaitre Vascular (LMAT) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Thu Aug 11, 1:33AM CDT
As of late, it has definitely been a great time to be an investor in LeMaitre Vascular Inc (LMAT).
LMAT: 18.35 (+0.59)
CVS Health (CVS) Tops Q2 Earnings, Lags on Revenue, View Up
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 3:39PM CDT
CVS Health Corporation (CVS) reported second-quarter 2016 adjusted earnings per share (EPS) of $1.32, up 8.2% year over year.
LMAT: 18.35 (+0.59), QDEL: 21.58 (-0.16), CVS: 93.84 (+0.47), NUVA: 66.74 (+0.68)
Omnicell (OMCL) Tops Q2 Earnings & Revenues, Margins Drag
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 3:36PM CDT
Omnicell, Inc. (OMCL) reported second-quarter 2016 adjusted earnings per share (EPS) of 29 cents reflecting year-over-year improvement of 61.1%.
LMAT: 18.35 (+0.59), QDEL: 21.58 (-0.16), OMCL: 38.88 (+0.58), NUVA: 66.74 (+0.68)
LeMaitre Vascular to Participate in the Canaccord Genuity 36th Annual Growth Conference on August 11, 2016
GlobeNewswire - Tue Aug 02, 3:26PM CDT
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that J.J. Pellegrino, Chief Financial Officer, will present at the Canaccord Genuity 36 Annual Growth Conference on Thursday, August 11, 2016 at the Intercontinental Hotel in Boston, MA.
LMAT: 18.35 (+0.59)
Cerus (CERS) in Focus: Stock Moves 6% Higher in Session
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 7:05AM CDT
Cerus Corporation (CERS) was a big mover last session, as the company saw its shares rise a little over 6% on the day.
CERS: 6.36 (unch), LMAT: 18.35 (+0.59)
LeMaitre Q2 2016 Record Sales $22.4mm (+13%), Record Op. Income $3.8mm (+35%)
GlobeNewswire - Wed Jul 27, 3:08PM CDT
LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, today reported Q2 2016 results, provided increased guidance, announced a $0.045/share dividend and authorized a $5.0mm share repurchase program.
LMAT: 18.35 (+0.59)
Genomic Health: Can the Liquid Biopsy Test Boost Margins?
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 7:50AM CDT
Genomic Health (GHDX) recently launched a next-generation sequencing blood-based mutational panel -- Oncotype SEQ Liquid Select.
BSX: 24.26 (-0.07), BAX: 46.28 (+0.10), LMAT: 18.35 (+0.59), GHDX: 27.12 (+0.45)
FDA Okays Trial for Medtronic's MRI-Guided Epilepsy Device
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 6:31AM CDT
With surgical procedures gaining ground in the treatment of drug-resistant epilepsy, the FDA go-ahead will expand Medtronic's (MDT) footprint in the billion-dollar neurosurgical market.
ICUI: 126.98 (+1.77), MDT: 87.32 (+0.34), BAX: 46.28 (+0.10), LMAT: 18.35 (+0.59)
Hologic: FDA Okays Procleix Zika Virus Test under IND Study
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 7:51AM CDT
Hologic's (HOLX) Procleix Zika Virus Test was approved under FDA???s Investigational New Drug (IND) study protocol to detect the presence of Zika virus in donated blood.
ICUI: 126.98 (+1.77), BAX: 46.28 (+0.10), LMAT: 18.35 (+0.59), HOLX: 38.51 (+0.05)
Walgreen Boots Hopeful on Rite Aid Buyout amid Margin Woes
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 7:26AM CDT
On Jun 22, 2016, we issued an updated research report on Walgreens Boots Alliance, Inc. (WBA).
WBA: 82.22 (+0.68), LMAT: 18.35 (+0.59), STJ: 78.65 (+0.51), NUVA: 66.74 (+0.68)
Qiagen's Q1 Results Hit by Currency, Competition Rife
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:32AM CDT
Qiagen (QGEN) is facing increasing competition from firms that provide pre-analytical solutions and other products.
BSX: 24.26 (-0.07), BAX: 46.28 (+0.10), LMAT: 18.35 (+0.59), QGEN: 26.63 (+0.17)
Hill-Rom Introduces VisiVest, First Connected Airways System
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 8:19AM CDT
Hill-Rom Holdings, Inc. (HRC) recently launched VisiVest System, the world's first wirelessly connected airway clearance system.
ICUI: 126.98 (+1.77), LMAT: 18.35 (+0.59), NUVA: 66.74 (+0.68), HRC: 59.97 (+0.72)
Hologic's Zika Virus Test Gets FDA Nod for Emergency Use
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 7:58AM CDT
Hologic (HOLX) will run the Aptima Zika virus test on its market leading Panther platform, which substantially reduces hands-on time for laboratories and the potential for manual errors.
ICUI: 126.98 (+1.77), BAX: 46.28 (+0.10), LMAT: 18.35 (+0.59), HOLX: 38.51 (+0.05)
AmSurg, Envision Healthcare Set to Merge by 2016-End
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 8:47AM CDT
Envision shareholders will own 53% of the combined entity while AmSurg (AMSG) shareholders will have 47%.
AMSG: 67.29 (+1.89), EVHC: 22.18 (+0.73), BAX: 46.28 (+0.10), LMAT: 18.35 (+0.59)
Genomic Health Brings Liquid Biopsy Test for Stage IV Cancer
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 7:13AM CDT
Genomic's (GHDX) Oncotype SEQ facilitates personalized treatment of patients suffering from stage four solid tumor cancer.
BAX: 46.28 (+0.10), LMAT: 18.35 (+0.59), ILMN: 167.90 (-0.66), GHDX: 27.12 (+0.45)
Qiagen???s QIAsure Test to Determine Cervical Cancer Risks
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 7:33AM CDT
Qiagen's (QGEN) QIAsure accurately stratifies cervical cancer risk, which offers highly sensitive and specific results for patients and clinicians.
BAX: 46.28 (+0.10), LMAT: 18.35 (+0.59), QGEN: 26.63 (+0.17), NUVA: 66.74 (+0.68)
Boston Scientific: NICE Backs GreenLight XPS for BPH Cure
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 7:01AM CDT
As per NICE's estimates, broad adoption of Boston Scientific's (BSX) GreenLight therapy over TURP can lead to savings of up to ??3.2 million annually for the National Health Service (NHS).
BSX: 24.26 (-0.07), BAX: 46.28 (+0.10), LMAT: 18.35 (+0.59), NUVA: 66.74 (+0.68)
LeMaitre Vascular to Attend the 9th Annual Barrington Research Fall Investment Conference on September 8, 2016
GlobeNewswire - Thu Aug 25, 4:43PM CDT
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that JJ Pellegrino, Chief Financial Officer, will present at the 9 Annual Barrington Research Fall Investment Conference on Thursday, September 8, 2016 at the Four Seasons Hotel in Chicago, IL.
LMAT: 18.35 (+0.59)
LeMaitre Vascular to Participate in the Midwest IDEAS Investor Conference on August 30, 2016
GlobeNewswire - Tue Aug 16, 3:32PM CDT
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that George W. LeMaitre, Chairman & CEO, will present at the Midwest IDEAS Investor Conference on Tuesday, August 30, 2016 at the Hard Rock Hotel in Chicago, IL.
LMAT: 18.35 (+0.59)
Moving Average Crossover Alert: LeMaitre Vascular (LMAT)
Zacks Equity Research - Zacks Investment Research - Tue Aug 16, 10:31AM CDT
LeMaitre Vascular, Inc. (LMAT) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
LMAT: 18.35 (+0.59)
Will LeMaitre Vascular (LMAT) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Thu Aug 11, 1:33AM CDT
As of late, it has definitely been a great time to be an investor in LeMaitre Vascular Inc (LMAT).
LMAT: 18.35 (+0.59)
CVS Health (CVS) Tops Q2 Earnings, Lags on Revenue, View Up
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 3:39PM CDT
CVS Health Corporation (CVS) reported second-quarter 2016 adjusted earnings per share (EPS) of $1.32, up 8.2% year over year.
LMAT: 18.35 (+0.59), QDEL: 21.58 (-0.16), CVS: 93.84 (+0.47), NUVA: 66.74 (+0.68)
Omnicell (OMCL) Tops Q2 Earnings & Revenues, Margins Drag
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 3:36PM CDT
Omnicell, Inc. (OMCL) reported second-quarter 2016 adjusted earnings per share (EPS) of 29 cents reflecting year-over-year improvement of 61.1%.
LMAT: 18.35 (+0.59), QDEL: 21.58 (-0.16), OMCL: 38.88 (+0.58), NUVA: 66.74 (+0.68)
LeMaitre Vascular to Participate in the Canaccord Genuity 36th Annual Growth Conference on August 11, 2016
GlobeNewswire - Tue Aug 02, 3:26PM CDT
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that J.J. Pellegrino, Chief Financial Officer, will present at the Canaccord Genuity 36 Annual Growth Conference on Thursday, August 11, 2016 at the Intercontinental Hotel in Boston, MA.
LMAT: 18.35 (+0.59)
Cerus (CERS) in Focus: Stock Moves 6% Higher in Session
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 7:05AM CDT
Cerus Corporation (CERS) was a big mover last session, as the company saw its shares rise a little over 6% on the day.
CERS: 6.36 (unch), LMAT: 18.35 (+0.59)
LeMaitre Q2 2016 Record Sales $22.4mm (+13%), Record Op. Income $3.8mm (+35%)
GlobeNewswire - Wed Jul 27, 3:08PM CDT
LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, today reported Q2 2016 results, provided increased guidance, announced a $0.045/share dividend and authorized a $5.0mm share repurchase program.
LMAT: 18.35 (+0.59)
Genomic Health: Can the Liquid Biopsy Test Boost Margins?
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 7:50AM CDT
Genomic Health (GHDX) recently launched a next-generation sequencing blood-based mutational panel -- Oncotype SEQ Liquid Select.
BSX: 24.26 (-0.07), BAX: 46.28 (+0.10), LMAT: 18.35 (+0.59), GHDX: 27.12 (+0.45)
FDA Okays Trial for Medtronic's MRI-Guided Epilepsy Device
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 6:31AM CDT
With surgical procedures gaining ground in the treatment of drug-resistant epilepsy, the FDA go-ahead will expand Medtronic's (MDT) footprint in the billion-dollar neurosurgical market.
ICUI: 126.98 (+1.77), MDT: 87.32 (+0.34), BAX: 46.28 (+0.10), LMAT: 18.35 (+0.59)
Hologic: FDA Okays Procleix Zika Virus Test under IND Study
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 7:51AM CDT
Hologic's (HOLX) Procleix Zika Virus Test was approved under FDA???s Investigational New Drug (IND) study protocol to detect the presence of Zika virus in donated blood.
ICUI: 126.98 (+1.77), BAX: 46.28 (+0.10), LMAT: 18.35 (+0.59), HOLX: 38.51 (+0.05)
Walgreen Boots Hopeful on Rite Aid Buyout amid Margin Woes
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 7:26AM CDT
On Jun 22, 2016, we issued an updated research report on Walgreens Boots Alliance, Inc. (WBA).
WBA: 82.22 (+0.68), LMAT: 18.35 (+0.59), STJ: 78.65 (+0.51), NUVA: 66.74 (+0.68)
Qiagen's Q1 Results Hit by Currency, Competition Rife
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:32AM CDT
Qiagen (QGEN) is facing increasing competition from firms that provide pre-analytical solutions and other products.
BSX: 24.26 (-0.07), BAX: 46.28 (+0.10), LMAT: 18.35 (+0.59), QGEN: 26.63 (+0.17)
Hill-Rom Introduces VisiVest, First Connected Airways System
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 8:19AM CDT
Hill-Rom Holdings, Inc. (HRC) recently launched VisiVest System, the world's first wirelessly connected airway clearance system.
ICUI: 126.98 (+1.77), LMAT: 18.35 (+0.59), NUVA: 66.74 (+0.68), HRC: 59.97 (+0.72)
Hologic's Zika Virus Test Gets FDA Nod for Emergency Use
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 7:58AM CDT
Hologic (HOLX) will run the Aptima Zika virus test on its market leading Panther platform, which substantially reduces hands-on time for laboratories and the potential for manual errors.
ICUI: 126.98 (+1.77), BAX: 46.28 (+0.10), LMAT: 18.35 (+0.59), HOLX: 38.51 (+0.05)
AmSurg, Envision Healthcare Set to Merge by 2016-End
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 8:47AM CDT
Envision shareholders will own 53% of the combined entity while AmSurg (AMSG) shareholders will have 47%.
AMSG: 67.29 (+1.89), EVHC: 22.18 (+0.73), BAX: 46.28 (+0.10), LMAT: 18.35 (+0.59)
Genomic Health Brings Liquid Biopsy Test for Stage IV Cancer
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 7:13AM CDT
Genomic's (GHDX) Oncotype SEQ facilitates personalized treatment of patients suffering from stage four solid tumor cancer.
BAX: 46.28 (+0.10), LMAT: 18.35 (+0.59), ILMN: 167.90 (-0.66), GHDX: 27.12 (+0.45)
Qiagen???s QIAsure Test to Determine Cervical Cancer Risks
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 7:33AM CDT
Qiagen's (QGEN) QIAsure accurately stratifies cervical cancer risk, which offers highly sensitive and specific results for patients and clinicians.
BAX: 46.28 (+0.10), LMAT: 18.35 (+0.59), QGEN: 26.63 (+0.17), NUVA: 66.74 (+0.68)
Boston Scientific: NICE Backs GreenLight XPS for BPH Cure
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 7:01AM CDT
As per NICE's estimates, broad adoption of Boston Scientific's (BSX) GreenLight therapy over TURP can lead to savings of up to ??3.2 million annually for the National Health Service (NHS).
BSX: 24.26 (-0.07), BAX: 46.28 (+0.10), LMAT: 18.35 (+0.59), NUVA: 66.74 (+0.68)
(0)
(0)Scroll down for more posts ▼